Proangiogenic effects : BPC 157 may also promote angiogenesis (new blood vessel formation)
It is not approved by the FDA for human consumption, therapeutic application, or veterinary use
Phase 1: Weeks 13 (Disc Repair Priority) BPC-157: 500mcg/day subQ TB-500: 2.5mg/week subQ GHK-Cu: 1mg/day subQ Focus: disc tissue repair, nerve decompression, anti-inflammation Activity: physical therapy, gentle mobility, no loading Phase 2: Weeks 48 (Add Recomp Layer) Continue Phase 1 stack Add CJC-1295 no DAC + Ipamorelin: 100mcg each, pre-bed This layer drives GH pulsatility for tissue remodeling and begins the body recomposition phase Activity: begin light lifting as cleared by PT Phase 3: Weeks 9+ (Maintenance and Fat Loss) TB-500: Drop to maintenance 1.25mg/week BPC-157: Can drop to 250mcg/day or 5 days/week CJC+Ipa: Continue pre-bed Optional add: Tesamorelin (12mg/day, 5 days/week) for visceral fat and GH optimization pairs well with CJC+Ipa Optional add: Retatrutide for more aggressive fat loss if that's a priority What to Expect: Recovery Timeline Weeks 12: Reduced acute nerve pain is often the first noticeable change
Better Understanding of Broad and Nonspecific Symptoms Drawing on the point above, symptoms of adrenal fatigue are so broad and nonspecific (like tiredness, sleep disturbances, and mood swings) that they can apply to many different conditions, leading to potential misdiagnosis and inappropriate treatment
They are designed to monitor the accuracy and precision of analytical procedures in clinical diagnostics for the quantitative determination of glutathione in whole blood
